ENOV Stock Analysis: Buy, Sell, or Hold?
ENOV - Enovis Corporation
$21.30
-0.67 (-3.05%)
▼
5d:
-2.29%
30d:
-19.5%
90d:
-2.52%
HOLD
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ENOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ENOV shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ENOV shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$38.59
Based on 7.9% avg growth
INTRINSIC VALUE TODAY
$23.96
11.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ENOV is currently trading at $21.30, which is considered oversold relative to its 30-day fair value range of $21.44 to $24.53. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.2) compared to its historical average (6.5). Remarkably, the market is currently pricing in an annual earnings decline of 7.2% over the next few years. This pessimistic expectation contrasts with the company's recent 153.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ENOV is showing sideways momentum. Immediate support is located at $20.55, while resistance sits at $24.58. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: ENOV has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $42.30 (+98.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ENOV is showing sideways momentum. Immediate support is located at $20.55, while resistance sits at $24.58. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: ENOV has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $42.30 (+98.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$21.44 -
$24.53
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 98.6% below Wall St target ($42.30)
Trading Range Analysis
30-Day Trading Range
$21.44 -
$24.53
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$20.55
Resistance Level
$24.58
Current Trend
Sideways
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.23
Wall Street Target
$42.30
(+98.6%)
Revenue Growth (YoY)
5.4%
Earnings Growth (YoY)
153.1%
Profit Margin
-49.9%
Valuation Discount vs History
-7.2% cheaper
PE vs Historical
5.2 vs 6.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.2%
(market-implied from PE analysis)
1-Year Target
$19.77
(-7%)
2-Year Target
$18.34
(-14%)
3-Year Target
$17.02
(-20%)
3-Yr Target (if PE normalizes)
(PE: 5→7)
$21.17
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 11.7%)
$123.58
(+480%)
Base:
(SPY PE: 5.2, Growth: 11.7%)
$29.66
(+39%)
Bear:
(PE: 4.4, Growth: 11.7%)
$25.21
(+18%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.2 to 6.5
Stabilization Target:
$26.49
(+24.4%)
PE Expansion Potential:
+24.4%
Share & Embed Analysis
Last updated: June 23, 2026 2:49 AM ET
Data refreshes hourly during market hours. Next update: 3:49 AM
Data refreshes hourly during market hours. Next update: 3:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENOV showing a specific setup today?
Insider Activity (6 Months)
6
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Oliver Engert
BUY
1000 shares
2026-03-13
Oliver Engert
BUY
1000 shares
2026-03-09
Oliver Engert
BUY
750 shares
2026-03-06
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 52 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 59 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 60 HOLD |
